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a  b  s  t  r  a  c  t
Two  gonadotrophin  releasing  hormone  (GnRH)  constructs  prepared  by  either  chemical  conjugation  to
keyhole  limpet  hemocyanin  (GnRH-KLH)  or  as  an  expressed  recombinant  fusion  protein  (Multimer)  were
evaluated  with  or without  adjuvants  (immunostimulating  complexes,  ISCOMs,  or cytosine-phosphate-
guanosine  oligodeoxynucleotides,  CpG  ODNs).  After  subcutaneous  administration  to  Balb/c  male  mice  at
Weeks 0, 2 and  4,  these  preparations  were assessed  for induction  of immune  responses  and  effects  on
reproductive  organs.  GnRH-KLH  plus  ISCOMs  formulation  induced  strong  IgG  immune  responses  from
Week  4 through  Week  12  resulting  in  consistent  reproductive  organ  atrophy  by Week  12 after  sub-
cutaneous  administration.  GnRH-KLH  plus  CpG  ODNs  generated  immune  responses  but no atrophy  of
reproductive  tissues  by Week  12.  Multimer  plus  ISCOMs  induced  poor  immune  responses  and  no  effects
on  reproductive  tissues  by Week  12.  In  the  absence  of additional  adjuvant,  none  of the  GnRH  constructs
induced  reproductive  organ  atrophy.  GnRH-KLH  induced  stronger  immune  responses  when  formulated
with ISCOMs  or CpG  ODN  compared  to Multimer.  GnRH-KLH  with  ISCOMs  could  be  an  effective  colloidal
alternative  for emulsion  GnRH  vaccine  formulations.
© 2014  Elsevier  Ltd. All  rights  reserved.
1. Introduction
Reproductive function in mammalian species is regulated by
the hypothalamic-pituitary-gonadal axis [1]. GnRH (also known as
LHRH, luteinizing hormone releasing hormone) is a decapeptide
synthesised in neuronal cell bodies in the preoptic area of the
anterior hypothalamus. Once secreted, GnRH is transported to the
anterior pituitary via the hypothalamic-pituitary portal system
[1]. It then stimulates production and release of the two  pituitary
hormones, follicle stimulating hormone (FSH) and luteinizing
hormone (LH), which play a critical role in the development
and regulation of gonadal functions, including the production of
gametes and sex steroid hormones. Targeting GnRH for contra-
ception or sterilisation can be effective in both males and females
Abbreviations: GnRH, gonadotrophin releasing hormone; KLH, keyhole limpet
hemocyanin; ISCOMs, immunostimulating complexes; CpG ODNs, cytosine-
phosphate-guanosine oligodeoxynucleotides.
∗ Corresponding author at: Commonwealth Scientific and Industrial Research
Organisation (CSIRO), Biosecurity Flagship, GPO Box 1700, Canberra, ACT 2601,
Australia. Tel.: +61 2 62464092.
E-mail address: Lyn.Hinds@csiro.au (L.A. Hinds).
[2–5], and GnRH neutralisation has been reported as a treatment
for hormone dependent malignancies such as prostate cancer [6].
One of the major challenges in developing and formulating an
effective contraceptive vaccine is achieving strong systemic immu-
nity against the selected reproductive antigen. The immunogenicity
of small endogenous non-immunogenic peptides (such as GnRH),
can be enhanced by chemically conjugating the peptide to a larger
immunogenic protein or peptide (e.g. tetanus toxoid, KLH or oval-
bumin) [6,7]. This can also be achieved by recombinant expression
of a fusion protein prepared by combination of multiple protein(s)
and/or peptide(s) [8–11]. For example, Talwar et al. [8] developed a
GnRH construct in which 5 GnRH peptides were interspersed with
4 immunogenic T cell epitopes from a range of known infectious
microbes.
Even when GnRH is conjugated to a larger protein or pep-
tide(s), additional adjuvants are required in the formulation for
a strong induction of immune responses [12,13]. Therefore it is
hypothesised that the use of additional adjuvants in a formulation
should increase overall immunogenicity and in turn inhibit fertility.
Many of the conventional immunological adjuvants, such as Fre-
und’s complete adjuvant (FCA), bacterial toxins and non-purified
crude agents (e.g. lipid A), induce strong stimulant effects but also
frequently induce adverse effects [14,15]. The critical importance
http://dx.doi.org/10.1016/j.vaccine.2014.07.075
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of developing a formulation that is both efficacious and free of
side effects for an animal reproductive vaccine was demonstrated
by the Vaxstrate® vaccine, which comprised a LHRH–ovalbumin
conjugate formulated with an oil emulsion adjuvant system [16].
Vaxstrate® was used in Australia during the 1990s but was with-
drawn due to side effects (e.g. 40% animals with abscesses) and poor
efficacy in the field [17].
Alternative reagents such as purified and/or receptor-specific
adjuvants [9,10] are being investigated to enhance efficacy and
reduce side effects. ISCOMs are a saponin containing lipophilic
cage-like structured immunostimulant with regulatory approval
for veterinary vaccines in various countries [18,19]. ISCOMs are
also of interest due to their cage-like structure which could incor-
porate a soluble antigen [20,21]. Another group of adjuvants are
CpG ODNs which have toll-like receptor (TLR-9) specific immunos-
timulant properties due to the presence of the CpG motif [22,23].
In this study, acellular mono-phasic aqueous adjuvants (ISCOMs
and CpG ODNs) have been selected for in vivo assessment with two
GnRH-constructs GnRH-KLH and Multimer in male mice. Immune
responses over time and effects on reproductive tissues have been
determined.
2. Materials and methods
2.1. Animals
Male Balb/c mice aged between 5 and 6 weeks were purchased
from Animal Resource Centre, Perth, Western Australia. All animal
studies were approved by the CSIRO Ecosystem Sciences Animal
Ethics Committee (approval numbers 10-01 and 13-04).
2.2. Experimental design
2.2.1. Trial 1: assessment of GnRH-KLH formulations
Five groups of 5 male mice received subcutaneous injections
of their respective treatment at Weeks 0, 2 and 4. The treatments
were: GnRH-KLH (50 g) with or without an adjuvant, (either
ISCOMs (10 g), CpG ODN-1826 (25 g) or CpG ODN-2006 (25 g))
and a negative control group received subcutaneous buffer injec-
tions (100 l). A sixth group (positive control) received a single
subcutaneous injection of GonaconTM (GnRH conjugated to Blue
Mollusc protein ∼100 g) at Week 0. For all subcutaneous injec-
tions, 100 l of formulation volume or buffer (phosphate buffer
saline (PBS)) was administered.
Animals were weighed weekly using a Persola balance (±0.5 g).
Blood samples were collected (see Section 2.3) between 0830 and
1100 h from each mouse at Weeks 0, 2 and 4 before subcutaneous
treatments of formulations, and at Weeks 6, 9 and 12.
2.2.2. Trial 2: assessment of Multimer formulations
Five groups of 5 male mice received subcutaneous injections
of their respective treatment at Weeks 0, 2 and 4. These treat-
ments were: Multimer (50 g) with or without an adjuvant (either
ISCOM (10 g) or CpG ODN-2006 (25 g)); GnRH-KLH with added
ISCOMs as in Trial 1, and a negative control group received sub-
cutaneous buffer injections (100 l). CpG ODN-2006 was  selected
over CpG ODN-1826 based on both reproductive tissue and immune
responses for treated animals in Trial 1. A sixth group (positive
control) received a single subcutaneous injection of GonaconTM
(∼100 g) at Week 0. For all the subcutaneous injections, 100 l
of formulation volume or buffer (PBS) was administered. Animals
were weighed and blood samples were collected as explained above
trial 1.
2.3. Sample collection
Peripheral blood (75–100 L) was collected from the saphenous
vein into a heparinised capillary tube (1.1–1.2 mm width; Chase,
Scientific Glass Inc., USA). The blood sample was transferred to a
400 L micro tube (Sarstedt Pty Ltd., Australia) and placed on ice.
Samples were then spun in an Eppendorf 5415R microcentrifuge
set at 9000 rpm (7500 × g) and 4 ◦C for 20 min. The plasma was
collected into aliquots and placed at −20 ◦C until needed.
At Week 12, mice were euthanased using 4% isofluorane in oxy-
gen (Laser Animal Health, Australia). When the mouse was under
deep anaesthesia, heart puncture was  used to collect approximately
1 mL  of blood into a heparinised tube. The mouse was then killed
by cervical dislocation and reproductive tissues dissected, weighed
and placed in Bouin’s fixative for histological examination.
2.4. Preparation of formulations
The GnRH-KLH construct was  synthesised by Biomatik lab-
oratories, Canada. It was prepared by chemically conjugating
keyhole limpet haemocyanin (KLH) to the modified GnRH pep-
tide (amino acid sequence: pEHWSYGLRPGGC) at the C terminus
using a sulfosuccinimidyl-4-(N-maleimidomethyl) cyclohexane-1-
carboxylate (sulfo-SMCC) coupling agent at a 1:1 ratio. GnRH-KLH
was initially dissolved in a small volume of phosphate buffer con-
taining 8 M urea followed by 10-fold dilution with PBS. ISCOMs
(Pfizer Animal Health, Australia) or CpG ODN (Sapphire Biosciences,
Australia) solution was added to the GnRH conjugate solution to
achieve specified concentrations for subcutaneous treatments (see
Section 2.2).
The Multimer construct comprised five oligonucleotide strands
coding for the GnRH decapeptide interspersed with four oligonu-
cleotide sequences coding for promiscuous T helper non B-cell
epitopes. These Th cell epitopes were from the circumsporozite pro-
tein of Plasmodium falciparum (T1), Mycobacterium tetani Tetanus
toxoid (T2), respiratory syncytial virus (T3) and measles virus
(T4). Multimer structure is GnRH-T1-GnRH-T2-GnRH-T3-GnRH-T4-
GnRH [8]. Multimer was  expressed and purified at National Wildlife
Research Center (NWRC), Fort Collins, CO, USA. Freeze dried Mul-
timer was dissolved in sterile water to obtain a construct solution
in sodium phosphate buffer pH 5.0.
GonaConTM vaccine, developed as a single-shot treatment, was
used as a positive control vaccine. It contains GnRH conjugated to
a blue mollusc protein emulsified in AdjuVacTM adjuvant [24,25].
AdjuvacTM adjuvant has been developed by NWRC and contains
small quantities of killed Mycobacterium avium in a stable water in
oil (w/o) emulsion. AdjuvacTM is similar to FCA in that it is a w/o
emulsion formulation but FCA contains Mycobacterium tuberculin.
2.5. Anti-GnRH plasma antibodies
Plasma samples were assayed for IgG antibodies against GnRH
using an ELISA. The following protocol was  used in order:
Coating buffer (50 L, 0.1 M carbonate bicarbonate buffer pH
9.6; Sigma Aldrich, Australia) containing 200 ng of GnRH conju-
gated to bovine serum albumin (GnRH-BSA) (Genscript, Australia)
was added per well of flat-bottom Nunc F96 MicroWellTM plates (In
vitro Technologies, Australia) in duplicate and incubated overnight
at 4 ◦C. Blocking buffer (200 L), sterile PBS with 0.5% Fraction V
BSA (Sigma Aldrich, Australia) was  added per well and incubated
at 37 ◦C for 2 h. Plasma (50 L of 1:50 dilution in PBS) was  added
per well, in duplicate, and incubated at 37 ◦C for 1 h. Goat anti
mouse IgG HRP-conjugated secondary antibody (Sigma Aldrich,
Australia) (50 L of 1:8000 dilution in PBS containing 0.5% BSA)
was added per well and incubated at 37 ◦C for 1 h. All wells were
washed 3 times with wash buffer (PBS with 0.05% (v/v) Tween 20
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(Sigma Aldrich, Australia)) between each incubation step. 50 L
of 3,3′,5,5′-tetramethylbenzadine dihydrochloride (TMB) substrate
(Sigma Aldrich, Australia) was added per well. The plates were
placed on a shaker (150 rpm) at room temperature and left to
develop for 10 min. The reaction was stopped by the addition of
50 L of 2 M sulphuric acid solution to each well. The absorbance of
each well was measured at 450 nm in a Thermo Labsystems Multi-
skan Ascent photometric plate reader (ThermoScientific, Australia)
and analysed with Ascent Software (v.2.4.2). Results are presented
as optical density (OD) values minus the OD readings for the blank
wells (containing PBS only) from the same plate. A result was con-
sidered positive if it was above the average Week 0 readings + 3 SD
(0.512 for Trial 1 or 0.557 for Trial 2).
2.6. Histology of reproductive tissues
After fixation in Bouin’s fluid for 24 h, a portion of the right
testis and of the caput (head) and cauda (tail) of the right epi-
didymis was processed by an automatic Medite Tissue Processing
Centre and embedded using a Medite TBS 88 Paraffin Embedding
System in a single paraffin wax block. Sections (5 m) were taken
using a Leica RM2255 Microtome and mounted onto premium glass
slides (Livingstone International Pty Ltd., Australia) and left to dry
on a heat mat  at 35 ◦C for 48–72 h. Slide sections were deparaf-
finised and rehydrated through a graded series of ethanol baths
and stained using a Gill’s haematoxlyin and eosin stain. After slides
were mounted and cover slipped, they were left to dry on a heat
mat  set at 35 ◦C for a further 4–8 h and stored in a covered slide
box.
Testis sections (three per animal) were observed under a Leica
Axioimager microscope and three to four representative photos
were taken. The diameter of thirty circular seminiferous tubules
was measured as described by Predes et al. [26] using AxioVision
Release software V.2.8.2. The caput and cauda sections of the epi-
didymis were observed for cell structure and presence of sperm.
The examinations were carried out without knowledge of the treat-
ment by randomly coding the samples and not revealing the codes
until after analysis was completed.
2.7. Statistical analysis
Data from the control and treatment groups were compared by
a one way analysis of variance (ANOVA) followed by Dunnett’s post
hoc test using Sigma Plot Version 12.0. For body weight, a two way
repeated measures ANOVA (using Graphpad Prism 6 software) was
performed followed by Dunnett’s post hoc test.
3. Results
3.1. Trial 1
3.1.1. Body weight
Mice gained or maintained their weight during the 12-week
trial. Animals in the GnRH-KLH plus ISCOMs group remained
healthy and alert but were significantly lighter (P < 0.05; range:
20–23 g) compared to the negative control group (range: 24–26 g),
from Week 8 to Week 12. All other treatment groups continued to
gain body mass between Week 6 and Week 12 (Fig. 1). One mouse
given GnRH-KLH with CpG ODN 1826 died from unknown causes
during Week 9.
3.1.2. Immune responses
All mice given a single injection of the GonaconTM vaccine had
GnRH-specific antibodies by Week 2, and four mice maintained this
response through to Week 12 (Fig. 2b). A similar immune response
was observed in mice given GnRH-KLH with ISCOMs (Fig. 2d). All
Fig. 1. Changes in body weight (mean ± SEM) of mice in the different treatment
groups in Trial 1. Solid arrows on x-axis indicate treatment times for all groups
except GonaconTM group which received a single treatment at Week 0 only. *P < 0.05,
**P  < 0.01, ***P < 0.001 (two way repeated measures ANOVA, followed by Dunnett’s
post hoc analysis).
mice treated with GnRH-KLH and CpG ODN 1826, showed an anti-
body response by Week 4 (Fig. 2f). Two mice given GnRH-KLH with
CpG ODN 2006 showed an antibody response by Week 4 through to
Week 12, with two others showing variable responses from Week
6 onwards (Fig. 2e). Mice given GnRH-KLH without an adjuvant
had measurable antibody responses by Week 6 (Fig. 2c). No GnRH-
specific immune responses were detected in any of the mice given
the negative control treatment (Fig. 2a).
3.1.3. Tissue weights
Three of five mice given GonaconTM showed decreases in testis,
epididymis and seminal vesicle/prostate gland weights; for the
overall group, however, only the average weight of the testes
showed a significant decrease (P < 0.05) (Table 1). All mice receiv-
ing the GnRH-KLH with ISCOMs treatment had significantly smaller
testes, epididymides and seminal vesicles/prostate gland weights
(P < 0.001) and heavier spleen weights (P < 0.01) compared with the
negative control mice. No other treatment group showed consistent
decreases in reproductive tissues (Table 1). However, some individ-
uals showed reproductive effects by Week 12 after the start of their
respective treatments. In one mouse given GnRH-KLH with CpG
ODN 2006 there was a reduction in all reproductive tissue weights
compared with the control mice. Its combined testes, combined
epididymides, and total seminal vesicle and prostate weights were
70 mg,  18 mg  and 18 mg,  respectively.
3.1.4. Histology of reproductive tissues
In mice which showed no changes in reproductive tissues
weights, all normal stages of spermatogenesis were observed
within the tubules of the testis and epididymis, and their semi-
nal vesicles were fluid filled (Fig. 3a, b, e, and f). By contrast at
Week 12, in all mice given GnRH-KLH with ISCOMs  the major-
ity of seminiferous tubules lacked a defined lumen and few to no
spermatozoa were present (Fig. 3c, d, g, and h). Spermatids were
absent, although spermatocytes and Sertoli cells were observed
(Fig. 3c). As atrophy occurred, the seminiferous tubules also became
significantly (P < 0.001) smaller in diameter (control = 199 ± 16 m
vs. GnRH-KLH plus ISCOMs = 121 ± 27 m)  (Fig. 3b and d).
The absence of spermatogenesis in the testis was  paralleled by
atrophy in the epididymis and seminal vesicles. The volume of
epithelial cells lining the epididymis was reduced, with almost no
sperm present in the fluid filled tubules (Fig. 3 g). These effects were
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Fig. 2. Anti-GnRH IgG antibody response profile (1:50 plasma dilution) for respective treatments in Trial 1. Arrows on x-axis indicate treatment times. Dashed line in the
graphs  represents the assay cut-off point.
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Fig. 3. Representative histological sections of mouse reproductive tissues at Week 12, from Trial 1. (a) and (b) Normal seminiferous tubules from a control animal; (c) and
(d)  degenerating and atrophied seminiferous tubules of a mouse treated with GnRH-KLH plus ISCOMs; (e) normal caput epididymis and (f) normal corpus epididymis from a
Control mouse; and (g) atrophied caput epididymis and (h) atrophied corpus epididymis of a mouse treated with GnRH-KLH plus ISCOMs. Scale bar (m) shown on each section.
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Table 1
Weights (mean ± SEM) of reproductive tissues and spleen at Week 12 for animals in different treatment groups in Trial 1.
Treatment No. of animals Spleen (mg) Testes (mg) Epididymides (mg) Seminal vesicles and prostate gland (mg)
Buffer only (negative control) 5 81.8 ± 4.6 219.0 ± 4.9 67.6 ± 2.4 289.8 ± 8.3
GonaConTM (Positive control) 5 99.0 ± 6.9 118.2 ± 27.6* 46.2 ± 10.5 125.4 ± 68.7
GnRH-KLH 5 85.2 ± 2.4 229.4 ± 5.2 71.4 ± 2.1 287.8 ± 29.8
GnRH-KLH + ISCOM 5 108.0 ± 3.5** 67.0 ± 11.8*** 22.8 ± 4.6*** 22.8 ± 9.3***
GnRH-KLH + CpG ODN 2006 5 84.0 ± 7.5 171.0 ± 27.3 58.0 ± 10.5 178.6 ± 46.7
GnRH-KLH + CpG ODN 1826 4 90.8 ± 2.3 191.8 ± 3.9 65.0 ± 3.2 260.5 ± 9.3
* P < 0.05 (one way  ANOVA followed by Dunnett’s post hoc analysis).
** P < 0.01 (one way  ANOVA followed by Dunnett’s post hoc analysis).
*** P < 0.001 (one way  ANOVA followed by Dunnett’s post hoc analysis).
Fig. 4. Body weight (mean ± SEM) of animals in different treatment groups during
the Trial 2. Solid arrows on x-axis indicate treatment times for all groups except
GonaconTM group which received a single treatment at Week 0 only. *P < 0.05,
**P < 0.01 (Two way  repeated measures ANOVA, followed by Dunnett’s post hoc
analysis).
also observed in 3 of 5 mice given the GonaconTM vaccine and 1 of
5 mice given GnRH-KLH with CpG ODN 2006 treatment.
3.2. Trial 2
3.2.1. Body weights
All groups showed increased body weights with time during the
trial (Fig. 4), similar to those observed in Trial 1. Animals treated
with GnRH-KLH with ISCOMs had significantly (P < 0.05) lower
mean body weights compared to negative control group from Week
9 to Week 12.
3.2.2. Immune responses
All mice given a single injection of the GonaconTM vaccine had
GnRH-specific antibodies by Week 4, and two mice maintained this
response through to Week 12 (Fig. 5b). Mice given GnRH-KLH with
ISCOM showed a strong immune response at Week 4 through to
Week 12 (Fig. 5c). Three mice administered with Multimer plus
ISCOMs showed immune responses by Week 4 but none of these
animals maintained the level to Week 12 (Fig. 5e). All other animals
treated with other formulations showed no anti-GnRH IgG immune
response (Fig. 5a and f).
3.2.3. Tissue weights
There was a significant decrease (P < 0.001) in the weights of
testes, epididymides and seminal vesicles/prostate gland weights
in mice receiving the GnRH-KLH with ISCOMs treatment compared
with the negative control mice (Table 2). All mice which received
ISCOM as part of their treatment had significantly heavier (P < 0.01)
spleen weights compared with the negative control mice (Table 2).
No other treatment group, including the positive control group
treated with GonaConTM, showed consistent decreases in repro-
ductive tissue weights (Table 2).
3.2.4. Histology of reproductive tissues
As in Trial 1, similar changes in the structure of the testis and
epididymis were observed in animals treated with GnRH-KLH with
ISCOMs group (data not shown).
4. Discussion
Over two  different trials subcutaneous treatment with GnRH-
KLH plus ISCOMs induced significant immune responses against
GnRH within 4 weeks of treatment and a subsequent significant
decrease in reproductive tissue size and weight by Week 12 after
the start of treatment. By contrast, while some individual mice
showed immune responses following treatment with Multimer
plus ISCOMs, these were not sustained and did not result in effects
at the reproductive level by Week 12 after start of treatment (Trial
2). Thus although the Multimer construct was immunogenic, it
likely requires the use of higher doses, and/or the addition of
a stronger adjuvant for the induction of uniform and sustained
responses. The significantly larger molecular size of GnRH-KLH
compared to Multimer could account for some of the differences
observed in immunogenicity of the two constructs. No other treat-
ments generated equivalent uniform immune responses or changes
in reproductive tissues to that of GnRH-KLH plus ISCOMs.
Many studies have reported the immunogenicity of different
GnRH constructs in various mammals, in the presence of unmo-
dified or modified FCA and/or Incomplete Freund’s adjuvant (IFA)
[8,27–29]. Beekman et al. [30] reported GnRH lipo-thioester and
GnRH lipo-amide formulated with FCA and/or IFA induced an anti-
GnRH immune response and immunocastration in pigs. However,
no significant decrease in testis weight and minimal anti-GnRH
antibody response was  observed in the same study when male
piglets were treated with GnRH lipo-amide incorporated in ISCOMs
[30]. Only a few studies [31,32] have induced an anti-GnRH immune
response and gonadal regression in the absence of Freund’s adju-
vants. Conforti et al. [31] reported CpG ODN 2006 as an efficient
replacement of FCA for a recombinant LHRH-ovalbumin fusion
protein antigen. Vaccine treatments using various doses of the anti-
gen emulsified with CpG ODN 2006 in mineral oil caused gonadal
regression and estrus suppression in heifers. In our trials, uniform
gonadal regression was  not observed after treatment with either
GnRH construct plus CpG ODN. This could be due to the use of dif-
ferent animal models (heifers vs. mice), and/or the duration of our
study. However, it is more likely due to their use of a mineral oil
emulsion base, similar to FCA, in their trial, whereas we  used only
phosphate buffer. The use of ISCOMs in two different trials gener-
ated stronger and more uniform adjuvant effects compared to CpG
ODNs with both GnRH-KLH and Multimer in the buffer base formu-
lations. ISCOMs have also been reported to be safe and effective as
an adjuvant by mucosal routes such as for intranasal vaccination
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Fig. 5. Anti-GnRH IgG antibody response profile (1:50 plasma dilution) for respective treatments in Trial 2. Arrows on x-axis indicate treatment times. Dashed line in the
graphs  represents the assay cut-off point.
Table 2
Weights (mean ± SEM) of reproductive tissues and spleen at Week 12 for animals in different treatment groups in Trial 2.
Treatment No. of animals Spleen (mg) Both testes (mg) Epididymides (mg) Seminal vesicles and prostate gland (mg)
Buffer only (negative control) 5 85.6 ± 3.8 239.4 ± 2.1 82.8 ± 4.6 258.6 ± 25.6
GonaconTM (positive control) 5 88.0 ± 1.2 225.8 ± 10.6 74.4 ± 1.0 256.6 ± 14.1
GnRH-KLH + ISCOM 5 107.0 ± 4.5*** 108.2 ± 19.5*** 34.4 ± 9.3*** 61.8 ± 35.2***
Multimer only 5 89.2 ± 3.0 226.0 ± 5.1 76.2 ± 1.0 284.2 ± 35.2
Multimer + ISCOM 5 103.2 ± 2.6** 226.6 ± 2.5 75.4 ± 0.7 283.2 ± 15.5
Multimer + CpG ODN 2006 5 89.6 ± 1.8 241.0 ± 5.8 77.2 ± 1.6 302.6 ± 12.2
** P < 0.01 (one way  ANOVA followed by Dunnett’s post hoc analysis).
*** P < 0.001 (one way  ANOVA followed by Dunnett’s post hoc analysis).
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[33–35]. Thus GnRH-KLH plus ISCOMs formulation trialled in our
study could not only be a model alternative for modified or non-
modified FCA/IFA based emulsion GnRH parenteral formulations
but also be a potential formulation for GnRH mucosal vaccination.
The significant difference between body weights of animals
administered with GnRH-KLH with ISCOMs compared to the neg-
ative control group in both trials by Weeks 8–9 could be the
result of diminished anabolic effects due to steroid deprivation
which might have occurred because of reproductive organ atro-
phy. Similar results have been reported for GnRH immunised
or castrated animals (various species) in many previous studies
[10,36,37]. Similarly, mean body weight of the group administered
with GonaconTM in Trial 1 was significantly less compared to nega-
tive control group (P < 0.05) at Week 9, although the difference was
not maintained through to Week 12 probably due to the variability
in reproductive organ atrophy among animals administered with
GonaconTM.
GonaconTM is very effective in inducing contraception after a
single injection in many different mammals although the effects are
generally more consistent in females than males [2,3,24,38]. In our
trials in male Balb/c mice, a single injection of GonaconTM induced
anti-GnRH immune responses and gonadal atrophy in some, but
not all of the mice. This variable response could indicate that the
administered dose was sub-optimal or that male Balb/c mice are
less sensitive to this vaccine compared to other mammals in which
it has been tested [38]. In our studies, animals injected with ISCOMs
formulations showed an enlarged spleen, an effect which could be
due to the presence of a saponin component; some saponin adju-
vants are known to possess an angiogenic effect and the spleen
enlargement may  thus be caused by increased blood supply [39,40].
For those mice which showed atrophy of the reproductive tis-
sues, it could be assumed they would be infertile given the absence
of spermatogenesis in the testis and absence of sperm in the epi-
didymis. The duration of infertility needs to be assessed in further
trials. Mice treated with GnRH-KLH plus ISCOMs also showed sig-
nificant decreases in prostate size; these effects indicate that the
GnRH-KLH plus ISCOMs formulation could be used as a model
system for the development of a potential immunotherapeutic
treatment of androgen-responsive prostate cancer.
To conclude, our results indicate that, under the same test con-
ditions, GnRH-KLH is more immunogenic compared to Multimer
in male Balb/c mice on subcutaneous administration. GnRH-KLH
induced more uniform and stronger immune responses when
administered with ISCOMs or CpG ODNs as adjuvants. However,
the GnRH-KLH plus ISCOMS was the only formulation which also
induced consistent reproductive organ atrophy in male Balb/c mice.
More studies are required to evaluate the efficacy of this formula-
tion by mucosal and parenteral routes.
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